Articles by Karen J. McGaughey, PhD
All-Cause Costs Increase Exponentially with Increased Chronic Kidney Disease Stage
ByLadan Golestaneh, MD, MS,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Alain Romero, PhD,Melanie S. Brenner, PharmD, BCPS,Macaulay Onuigbo, MD, MSc, MBA Evaluation of Clinical Outcomes and Costs Based on Prescribed Dose Level of Renin-Angiotensin-Aldosterone System Inhibitors
ByMurray Epstein, MD,Paula J. Alvarez, RPh, MPH, MBA,Nancy L. Reaven, MA,Susan E. Funk, MBA, FACHE,Karen J. McGaughey, PhD,Melanie S. Brenner, PharmD, BCPS,Wade Benton, PharmD,Ladan Golestane Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors
ByMurray Epstein, MD,Nancy L. Reaven, MA,Susan E. Funk, MBA,Karen J. McGaughey, PhD,Nina Oestreicher, PhD,John Knispel, MD